Nordea Investment Management AB Buys 1,243 Shares of The Cooper Companies, Inc. $COO

Nordea Investment Management AB boosted its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 7.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,976 shares of the medical device company’s stock after acquiring an additional 1,243 shares during the period. Nordea Investment Management AB’s holdings in Cooper Companies were worth $1,209,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new stake in Cooper Companies in the first quarter valued at $33,000. J.Safra Asset Management Corp boosted its holdings in shares of Cooper Companies by 204.8% during the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after buying an additional 340 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Cooper Companies during the 1st quarter valued at $40,000. Larson Financial Group LLC boosted its holdings in shares of Cooper Companies by 1,071.0% during the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock valued at $61,000 after buying an additional 664 shares in the last quarter. Finally, HM Payson & Co. boosted its holdings in shares of Cooper Companies by 147.4% during the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock valued at $75,000 after buying an additional 532 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Insiders Place Their Bets

In other Cooper Companies news, EVP Brian G. Andrews bought 1,525 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was acquired at an average price of $65.68 per share, with a total value of $100,162.00. Following the transaction, the executive vice president owned 22,191 shares in the company, valued at $1,457,504.88. This represents a 7.38% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Gerard H. Warner III bought 1,450 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was acquired at an average cost of $69.23 per share, with a total value of $100,383.50. Following the transaction, the chief operating officer owned 18,319 shares in the company, valued at $1,268,224.37. The trade was a 8.60% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 17,975 shares of company stock worth $1,216,346 in the last quarter. Insiders own 1.98% of the company’s stock.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $74.52 on Friday. The stock has a market cap of $14.82 billion, a price-to-earnings ratio of 36.71, a PEG ratio of 1.95 and a beta of 1.02. The firm’s 50-day moving average is $69.67 and its 200 day moving average is $73.22. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $109.04. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the business posted $0.96 EPS. Cooper Companies’s revenue was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has authorized a share buyback program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

A number of analysts have recently commented on COO shares. The Goldman Sachs Group set a $64.00 target price on shares of Cooper Companies and gave the company a “sell” rating in a report on Wednesday, October 1st. Wall Street Zen cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Piper Sandler dropped their target price on shares of Cooper Companies from $105.00 to $83.00 and set an “overweight” rating on the stock in a report on Thursday, August 28th. Barclays started coverage on shares of Cooper Companies in a report on Monday, October 13th. They set an “overweight” rating and a $85.00 target price on the stock. Finally, Robert W. Baird dropped their target price on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.